Skip to main content
. 2013 Feb 14;62(3):732–742. doi: 10.2337/db12-0548

FIG. 2.

FIG. 2.

MS275 ameliorates insulin resistance in db/db mice. A: Body weight of db/db mice treated with vehicle or HDAC inhibitors for 23 days (n = 10 per group). B and C: Fasting plasma glucose and insulin levels measured at day 23 of the treatment. D: Glucose tolerance test (GTT) performed on day 8 of treatment. E: Fasting serum triglycerides, nonesterified fatty acids (NEFA), and FPLC profile of plasma triglycerides of db/db mice treated with vehicle, SAHA, MS275, or MC1568. (FPLC samples are pools of 10 mice.) F: Hematoxylin-eosin (H&E) stain of liver sections from db/db mice treated with HDAC inhibitors. Data are presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control. C and CTRL, control; MC, MC1568; MS, MS275; S, SAHA. (A high-quality color representation of this figure is available in the online issue.)